TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who were diagnosed with the complete or incomplete type of Behcet's disease according to The criteria for a diagnosis of Behcet's disease, Ministry of Health, Labour and Welfare in Japan (partially revised in 2010)~* Patients who have special lesions despite having received conventional treatments for special lesions, or patients who cannot receive conventional treatments due to intolerability.~* Patients who have clinical symptoms associated with each special lesions.~Exclusion Criteria:~* Patients with intestinal, neuro-, vascular Behcet's disease in whom a differential diagnosis of each Behcet's disease from other conditions．~* Patients who have received treatment with infliximab within 1 year before enrollment for another purpose than treating special lesions; or patients whose previous treatment with infliximab was discontinued due to adverse events.~* Patients who had participated in another clinical study and had received a study drug within 12 weeks before giving acquirement.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TA-650 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 2 to 59 months in September 2007~Exclusion Criteria:~* history of allergy to study drugs

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 59 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): sulfalene pyrimethamine plus amodiaquine
- 2 (Type: ACTIVE_COMPARATOR): dihydroartemisinin piperaquine
- 3 (Type: ACTIVE_COMPARATOR): sulfadoxine-pyrimethamine plus piperaquine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-histamines Promote Electroacupuncture Analgesia: Basic and Clinical Research

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. . Age: 20 to 30 years of age.~2. . Agrees to undergo a comprehensive medical history and physical examination.~3. . No history of analgesic, sedative, dietary/appetite medication intake for more than 3 weeks prior to enrolment.~Exclusion Criteria:~1. . An ongoing medical condition that requires active medical intervention or monitoring to avert serious danger to the participant's health or well-being (e.g., hypertension, diabetes mellitus, or epilepsy).~2. . A compromised skin barrier (e.g., skin disease, allergy) that would interfere with the conduct of the EA procedure and assessments of the study.~3. . An implant such as a pacemaker, defibrillator, or electronic medical equipment.~4. . Pregnancy, or planning for pregnancy.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- sham EA group (Type: SHAM_COMPARATOR): Minimal needling at ST36 and GB34 (n=10)
- true EA group (Type: EXPERIMENTAL): EA at ST36 and GB34 (n=10)
- EA+antihistamine(low dose) group (Type: ACTIVE_COMPARATOR): EA at ST36 and GB34 plus low-dose chlorpheniramine( Dexchlorpheniramine maleate 2mg/tab, 1 tab; n=10)
- EA+antihistamine(high dose) group (Type: ACTIVE_COMPARATOR): EA at ST36 and GB34 plus high-dose chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 2 tabs; n=10)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or female medical non-ICU patients aged 18 - 70 years.~2. A known history of type 2 diabetes \> 3 months, receiving either diet alone, oral antidiabetic agents (excluding DPP4 inhibitors), or low-dose (≤ 0.5 units/kg/day) insulin therapy.~3. Subjects with BG \>180 mg and \< 400 mg/dL at the time of randomization without laboratory evidence of diabetic ketoacidosis (serum bicarbonate \< 18 mEq/L or positive serum or urinary ketones).~4. Written informed consent.~Exclusion Criteria:~1. Age \< 18 or \> 70 years.~2. Subjects with increased BG concentration but without a history of diabetes (stress hyperglycemia).~3. Subjects with a history of type 1 diabetes.~4. Patients with a history of diabetic ketoacidosis or hyperosmolar state.~5. Acute critical illness or coronary artery bypass graft (CABG) surgery is expected to require admission to a critical care unit.~6. Subjects with gastrointestinal obstruction, adynamic ileus, or those expected to require gastrointestinal suction.~7. Unable to take oral food or medications.~8. Patients with clinically relevant pancreatic or gallbladder disease.~9. Patients with significant hepatic disease (Child-Pugh score B or C) or impaired renal function (GFR \< 50 ml/min).~10. Treatment with oral or injectable corticosteroid.~11. Mental condition renders the subject unable to understand the study's nature, scope, and possible consequences.~12. Female subjects are pregnant or breastfeeding at the time of enrollment into the study.~13. Hypersensitivity to sitagliptin or another contraindication to DPP4 inhibitors.~14. Subject unable to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin + glargine (Type: EXPERIMENTAL): Sitagliptin and glargine once daily + correction doses of lispro if needed.
- Basal-plus (Type: ACTIVE_COMPARATOR): Glargine once daily plus correction doses of lispro if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Registry of Use and Application of Sensor Augmented Pump (SAP) Therapy Under Daily Life Conditions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients with signed informed consent~* Type 1 DM and has been on insulin pump therapy for at least 3 months prior to signature of the informed consent~* patients use CGM component as part as part of the continuous subcutaneous insulin infusion (CSII) therapy for a minimum of 1 month~Exclusion Criteria:~* participation in any other trial~* any disease or drug treatment that can interfere with the outcome of sensor usage~* using CGM in CSII \< 3 days/week~* patients not willing to sign informed consent~* abuse of alcohol or drugs (exception of nicotine consumption)~* eating disorder, anorexia, bulimia or other mental disorders

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: None): Patients treated with sensor augmented pump (SAP) therapy with insulin pump Paradigm VEO® and use continuous glucose monitoring (CGM).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aminophylline and Cognitive Function After Sevoflurane Anaesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA I-II patients~2. aged 18-55 years~3. scheduled for elective ambulatory surgery~4. duration \>1 h under general anaesthesia~Exclusion Criteria:~1. cardiovascular diseases~2. respiratory diseases~3. neurological diseases~4. psychiatric diseases~5. pregnancy~6. obesity~7. adverse reaction to aminophylline or sevoflurane~8. receiving xanthines, ß-agonist, anticholinergic~9. history of cognitive dysfunction~10. cerebrovascular disease~11. recent history of infection or recent fever~12. adverse reaction to aminophylline or sevoflurane~13. alcoholism~14. drug dependence~15. those receiving xanthines, ß-agonist, anticholinergic, tranquilizers, anticonvulsants or antidepressants~16. those who has habitual coffee consumption exceeding 2 cups per day~17. unable to read~18. suffering from serious hearing or vision impairment~19. those who had not completed primary school

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo [group P] (Type: PLACEBO_COMPARATOR): None
- Aminophylline 2 mg/Kg [group A2] (Type: ACTIVE_COMPARATOR): None
- Aminophylline 3 mg/Kg [group A3] (Type: ACTIVE_COMPARATOR): None
- Aminophylline 4mg/Kg [group A4] (Type: ACTIVE_COMPARATOR): None
- Aminophylline 5 mg/Kg [group A5] (Type: ACTIVE_COMPARATOR): None
- Doxapram 1 mg/kg [group D] (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a diagnosis of type 2 diabetes mellitus~* Must have inadequate diabetes control (as defined by glycosylated hemoglobin level \>=7.0% to \<=10.5% at screening)~* Greater than or equal to (\>=) 30 yrs old with history of cardiovascular (CV) event, or \>= 50 yrs old with high risk of CV events~* Must be either not on antihyperglycemic agents (AHA) therapy, or on AHA monotherapy, or combination AHA therapy with any approved agent for the control of blood glucose levels.~Exclusion Criteria~* History of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* History of one or more severe hypoglycemic episode within 6 months before screening~* History of hereditary glucose-galactose malabsorption or primary renal glucosuria~* Ongoing, inadequately controlled thyroid disorder~* Renal disease that required treatment with immunosuppressive therapy or a history of chronic dialysis or renal transplant~* Myocardial infarction, unstable angina, revascularization procedure, or cerebrovascular accident within 3 months before screening.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (JNJ-28431754) (Type: EXPERIMENTAL): Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive placebo (inactive medication) once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Internal Jugular Vein Compression Collar for Novel Symptomatic Treatment of Venous Pulsatile Tinnitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Male or female age 18 years and older~* Diagnosis of venous pulsatile tinnitus~* Patient at UNC ENT Meadowmont Clinic~Exclusion Criteria~* Increased presence of acid in the body or excessive blood alkalinity~* Open head injury (including in or around the eye) within the past six months~* Pseudotumor cerebri (false brain tumor)~* Presence of brain or spinal shunt~* Known seizure disorder~* Known airway obstruction~* Increased likelihood of blood clotting (coagulation)~* Skin injury, rash, or other abnormality on or around the neck~* age \<18~* unable to provide written consent,~* history of neurological deficits,~* previous cerebral infarction (blockage or narrowing in the arteries supplying blood and oxygen to the brain)~* severe head trauma~* medical contraindications to restriction of blood outflow via the internal jugular veins~* glaucoma (narrow angle or normal tension - increased pressure in the eyes),~* hydrocephalus (increased fluid on the brain)~* recent penetrating brain trauma (within 6 months),~* known carotid hypersensitivity~* known increased intracranial pressure~* idiopathic intracranial hypertension~* known intracranial vascular malformation (e.g. aneurysm, arteriovenous malformation, cavernoma)~* central vein thrombosis~* not tolerating initial fitting of collar.~* Known pregnancy (this is not a direct contraindication but is being made out of an abundance of caution)~* Inability to speak or comprehend English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Device will be fitted and worn up to two hours daily and participants will log changes in symptom intensity before and during device usage

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is informed and given ample time and opportunity to think about her/his participation in this extension trial and has given her/his written informed consent~* Subject met all inclusion criteria defined in the SP611 trial with SPM927 at the time of enrollment into trial SP611~* Subject has successfully completed trial SP611 and, in the investigator's opinion, would benefit from long-term administration of SPM927~* Subject is willing and able to comply with all trial requirements, including the ability to complete trial questionnaires~Exclusion Criteria:~* Subject previously participated in this trial~* Subject has participated in another trial of an investigational drug within the last 3 months (excluding trial SP611) or is currently participating in another trial of an investigational drug~* Subject has had prior therapy with a Nonsteroidal Anti-inflammatory Drug (NSAID) or Anti-epileptic Drug (AED) within 28 days prior to the Eligibility Visit~* Subject has evidence or history of significant Cardiovascular Disease within 12 months prior to the Eligibility Visit~* Subject has laboratory values, which are outside the normal range and judged by the Investigator to be clinically significant~* Subject has abnormal Renal or Hepatic function~* Subject has a history of Malignancies with the exception of subjects with a documented disease-free interval of 5 years or more~* Subject has a history of chronic alcohol or drug abuse within the last 12 months~* Subject has any medical or psychiatric condition which, in the opinion of the Investigator, could jeopardize or compromise the subject's ability to participate in this continuation trial~* Subject with a known history of severe Anaphylactic Reaction and/or serious or life threatening Blood Dyscrasias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Open-label active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraarterial Nitroglycerin Versus Nicardipine and Radial Artery Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing transradial catheterization~Exclusion Criteria:~* Systolic blood pressure \< 100 mmHg

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nitroglycerin (Type: ACTIVE_COMPARATOR): 500 microgram intraarterial Nitroglycerin
- Nicardipine (Type: PLACEBO_COMPARATOR): 200 microgram intraraterial Nicardipine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are diagnosed with acute SAC and experience at least grade 4 ocular itching and at least grade 2 bulbar conjunctival injection (redness) in each eye due to seasonal allergy at Visit 1.~Exclusion Criteria:~* Subjects who have a known hypersensitivity to the study medications or their components or contraindications to ocular corticosteroids.~* Subjects who use any of the disallowed medications throughout the duration of the study and during the period indicated prior to Visit 1.~* Subjects who have intraocular pressure (IOP) greater than 21 mm Hg in either eye or any type of glaucoma.~* Subjects who have a history of any severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study or affect the subject's safety or trial parameters.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alrex (Type: EXPERIMENTAL): Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%
- Patanol (Type: ACTIVE_COMPARATOR): Ophthalmic solution containing olopatadine, 0.1%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with mycosis fungoides confirmed by a skin biopsy~* Stage I or IIA patients must have been treated previously with prior topical therapies including PUVA, UVB, topical steroids, but not NM within the past 2 years, or topical carmustine (BCNU)~* Patients must be otherwise healthy with acceptable organ function.~* Prior to initiating study therapy, patients must not have had topical therapy within four weeks~* Lab values within normal range~* Willing/able to give consent~* Must use effective means of contraception if of childbearing potential~Exclusion Criteria:~* Newly diagnosed mycosis fungoides with no prior therapy~* A prior history of treatment with topical NM within the past 2 years or topical carmustine (BCNU)~* Use of topical or systemic therapies for MF within four (4) weeks of entry in the study~* Patients with a diagnosis of stage IIB-IV MF~* Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent compliance with the requirements of the treatment program~* Pregnant or nursing females, or males and females of childbearing potential, not using an effective means of contraception~* Patients who have had radiation therapy within one year of study start~* Patients who have a history of a higher T score than T2 or a higher N score than N1~* Patients who do not agree to do all labs at one site

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (PG - NM (MCH) 0.02%) (Type: ACTIVE_COMPARATOR): PG - mechlorethamine-MCH (nitrogen mustard) 0.02% gel To evaluate the tolerability and safety of topical mechlorethamine-MCH (nitrogen mustard) 0.02% ointment formulations in patients with stage I or IIA MF
- 2 (AP - MCH(NM) 0.02%) (Type: ACTIVE_COMPARATOR): AP - mechlorethamine-MCH (nitrogen mustard) 0.02% compounded in Aquaphor To evaluate the tolerability and safety of mechlorethamine-MCH (nitrogen mustard)0.02% ointment formulations in patients with stage I or IIA MF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
To qualify for this trial, you must have ALL of the following:~* Histologically documented adenocarcinoma of the prostate~* Cancer that has progressed while on adequate hormone therapy. This state of the disease is androgen independent prostate cancer (AIPC).~* Cancer that has spread outside the prostate (metastatic) to lymph nodes or bone. Please note that if your cancer has spread to organs (e.g., liver, lung, brain), you are not eligible for the study.~* The absence of or minimal current cancer-related pain~Please note that there are additional eligibility criteria. The study center will determine if you meet all of the criteria.~Study personnel will explain the trial in detail and answer any questions you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, study personnel will explain the reasons.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APC-Placebo (Type: PLACEBO_COMPARATOR): None
- Sipuleucel-T (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete